The World Health Organization’s new guidance against pharmacological intervention for childhood obesity under age ten marks a watershed moment in pediatric medicine—not because it eliminates a treatment option, but because it forces an uncomfortable reckoning with what we actually mean by “evidence-based care” when the evidence points toward interventions that health systems have systematically underfunded for decades.
Let me be direct: the guidelines are scientifically sound. The pharmacological arsenal for pediatric obesity—GLP-1 receptor agonists, orlistat, and proposed agents in development—carries metabolic and psychological risks in children whose bodies are still developing, whose relationship with food and self-image remains malleable, and whose long-term medication adherence cannot be reliably predicted. The evidence supporting behavioral and lifestyle intervention as first-line therapy in this age group is robust. On this, there is little genuine dispute among pediatric endocrinologists or obesity medicine specialists.
But here is where the editorial caution must enter: a guideline is not a treatment. A recommendation without resources is merely an aspiration dressed in the language of authority.
For the past two decades, obesity medicine has operated within a peculiar contradiction. Pharmaceutical solutions—however imperfect—arrived with reimbursement pathways, marketing infrastructure, and clinical workflows already in place. A child prescribed a GLP-1 agonist receives a defined intervention with measurable adherence. A family referred to intensive lifestyle modification receives… often very little. Overworked pediatricians offer standard counseling. Insurance rarely covers dietitian consultation. Community programs exist patchily, if at all. Parents, already stretched by work and competing demands, are asked to orchestrate the behavioral equivalent of open-heart surgery with no surgical team.
The WHO guidelines are correct that we should not medicate children’s obesity when behavioral intervention remains the first-line option. But this correctness contains a hidden premise: that behavioral intervention is actually available and adequately resourced. For many health systems—and I include Georgia’s own, despite our improvements—this premise remains counterfactual.
Consider what intensive, evidence-based behavioral intervention for childhood obesity actually requires. It demands multidisciplinary teams: pediatricians, registered dietitians, exercise physiologists, behavioral psychologists, sometimes social workers. It requires sustained engagement—not one visit, but serial visits over months to years. It involves family systems work, food environment modification, school coordination, and often navigation of food insecurity and poverty. It is labor-intensive, time-intensive, and therefore expensive. Yet in most reimbursement systems, it is either unfunded or reimbursed at rates that make delivery economically unsustainable.
The pharmaceutical industry, for all its faults, has created at least a clear economic pathway for treatment. A pill or injection has a defined production cost, a patent life, a pricing model. Behavioral intervention has none of these. It is chronically underfunded relative to demand because no commercial entity profits from its delivery and because health systems have not adequately prioritized prevention as a budget line.
So the WHO guidelines present us with a choice, not a solved problem. We can implement them as written—prohibiting pharmacotherapy under ten and committing ourselves to resourced, evidence-based behavioral medicine. Or we can implement them as a de facto treatment withdrawal, leaving families of obese children under ten with no effective options, neither pharmaceutical nor behavioral.
My position, and I state it clearly: I support the WHO guidelines. The pharmacological risks for this age group outweigh the demonstrated benefits, and behavioral intervention represents the appropriate first line. But I do so with the explicit condition that health systems must now treat this guideline as a mandate not only for what we *will not* do, but for what we *must* do with adequate funding, adequate staffing, and adequate time.
In Georgia, as in most countries, this means a reckoning. It means training more pediatric dietitians and behavioral health specialists. It means restructuring reimbursement to make family-based intervention economically viable for healthcare providers. It means recognizing that childhood obesity is not primarily a problem of insufficient willpower in families, but a systems problem of insufficient investment in the behavioral medicine that guidelines now demand we provide.
The WHO has given us evidence-based guidance. It now falls to us to create evidence-based health systems capable of implementing it. Without that commitment, these guidelines risk becoming another example of the gap between what medicine knows is right and what health systems actually deliver.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
